Insulet Corporation enters the week of July 7 with a striking divergence: options traders have rarely been this bullish on the stock, even as short sellers quietly rebuild positions and the Street cuts targets ahead of August earnings.
The options market is the clearest signal this week. The put/call ratio has collapsed to 0.41 — nearly 1.7 standard deviations below its 20-day average of 0.62, and within a whisker of its 52-week low of 0.37. That means call buyers are dominating the options tape at a level that is almost unprecedented over the past year. The shift has been rapid: through most of June, the PCR ran in the 0.69–0.73 range. Since late June it has fallen off a cliff. Whether this reflects genuine conviction ahead of the August 5 Q1 print, or simply a mechanical chase of the stock's 6% weekly gain, the options tape is unambiguously leaning long.
Short interest tells a more complicated story. Bears have been rebuilding. SI has risen roughly 70% over the past month, from around 3 million shares in early June to 5.1 million now — 7.3% of the free float. That is a meaningful position, and the rebuild was sharp. The past week has been quieter, with SI edging down 0.7%, suggesting the buildup may be pausing rather than accelerating. The borrow market offers no signal of urgency: availability remains extraordinarily loose at over 6,600% of outstanding short interest, and the cost to borrow is a negligible 0.50%. There is no squeeze pressure, no borrow scarcity, and no mechanical feedback loop in the lending market. Bears can add at will. Positioning looks contested rather than one-sided — bulls in the options pits, shorts in the equity lending market.
The Street reflects the same tension. The consensus direction of analyst moves over the past six weeks has been unmistakably downward on price targets, even among bulls. BofA cut from $288 to $208 in May, Truist trimmed from $250 to $219 in June, and Evercore ISI this week lowered its target from $200 to $180 while holding an Outperform rating. Citigroup today nudged its target up marginally to $172, maintaining Neutral — a target that sits barely above the current $161.55 price, implying the sideline camp sees little runway. Deutsche Bank initiated with a Buy and a $190 target in late June. The mean consensus target of $240 carries an implied 49% upside, but the direction of travel in recent weeks has been lower, not higher. Factor scores offer a nuanced backdrop: EPS momentum ranks in the 66th–73rd percentile over 30- and 90-day windows, and the analyst recommendation differential ranks in the striking 95th percentile — meaning the gap between where analysts are and where they are heading is unusually wide. The bull case rests on 20% revenue growth and Omnipod's pharmacy channel moat; the bear case centres on GLP-1 headwinds to long-term insulin pump demand and ongoing competitive pressure in the patch pump space.
Board-level buying in early June adds an interesting footnote. The Independent Chairman purchased 3,450 shares at $144.20, and a fellow Independent Director added 2,790 shares at $143.51 — together representing roughly $900,000 of open-market buying. The net 90-day insider figure is modestly positive at $1.2 million. These were board members, not operating executives, and the CEO sold in May at $148.84. The insider signal is mixed rather than a clear directional flag, but the board purchases at prices well below today's $161.55 are worth noting.
PODD's next major test is the August 5 earnings release. The prior two prints produced small positive day-one moves of roughly 1.5–1.9%, followed by five-day losses of 1.7–5.6%, suggesting the stock has tended to fade after initial relief rallies. With shorts rebuilt to a 12-month high and options traders pricing in notable upside, how the August print lands — and what management says about the voluntary device correction and GLP-1 competitive risk — will determine which of these two camps gets vindicated.
See the live data behind this article on ORTEX.
Open PODD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
